Advertisement

ADVERTISEMENT

Ovarian Cancer

Videos
Rucaparib vs Chemotherapy for Platinum-Sensitive Patients With Advanced Ovarian Cancer
06/23/2021
David O'Malley, MD, discusses results from a subgroup analysis of the ARIEL4 trial, comparing rucaparib vs chemotherapy among platinum-sensitive patients with ovarian cancer.
David O'Malley, MD, discusses results from a subgroup analysis of the ARIEL4 trial, comparing rucaparib vs chemotherapy among platinum-sensitive patients with ovarian cancer.
David O'Malley, MD, discusses...
06/23/2021
Journal of Clinical Pathways
Conference Coverage
An International Analysis of Treatments and Outcomes Among Patients with Epithelial Ovarian Cancer
06/17/2021
A new study suggests variation in patient populations between sites, and differences in treatments and outcomes across international networks of epithelial ovarian cancer treatment centers.
A new study suggests variation in patient populations between sites, and differences in treatments and outcomes across international networks of epithelial ovarian cancer treatment centers.
A new study suggests variation...
06/17/2021
Journal of Clinical Pathways
Conference Coverage
Real-World PARP Inhibitor Toxicities in Ovarian Cancer Consistent With Clinical Trials
06/07/2021
In routine clinical practice, toxicities from PARP inhibitor therapy in patients with relapsed ovarian cancer are low grade and occur early in treatment, consistent with phase 3 trials clinical trials.
In routine clinical practice, toxicities from PARP inhibitor therapy in patients with relapsed ovarian cancer are low grade and occur early in treatment, consistent with phase 3 trials clinical trials.
In routine clinical practice,...
06/07/2021
Journal of Clinical Pathways
Conference Coverage
Real-World Utilization of Second-Line Maintenance Therapy for Patients With Ovarian Cancer
06/07/2021
Fewer than half of eligible patients with advanced ovarian cancer receive second-line maintenance therapy, according to results from a real-world analysis.
Fewer than half of eligible patients with advanced ovarian cancer receive second-line maintenance therapy, according to results from a real-world analysis.
Fewer than half of eligible...
06/07/2021
Journal of Clinical Pathways
Conference Insider
The Role of CD10 Expression in enMSC on the Progression of EAC
06/03/2021
Experts determine the Role of CD10 expression in endometriosis-associated mesenchymal stem cells on the progression of endometriosis-associated carcinoma, presented at the 2021 ASCO Annual Meeting.
Experts determine the Role of CD10 expression in endometriosis-associated mesenchymal stem cells on the progression of endometriosis-associated carcinoma, presented at the 2021 ASCO Annual Meeting.
Experts determine the Role of...
06/03/2021
Oncology
Conference Insider
Pafolacianine Sodium, NIRF Imaging Adjunct May Yield Benefit in FR+ Ovarian Cancer
06/01/2021
Experts reveal pafolacianine sodium may offer a novel real-time adjunct to current surgical imaging practice in ovarian cancer surgery, according to a phase 3 study being presented at the virtual 2021 American Society of Clinical Oncology...
Experts reveal pafolacianine sodium may offer a novel real-time adjunct to current surgical imaging practice in ovarian cancer surgery, according to a phase 3 study being presented at the virtual 2021 American Society of Clinical Oncology...
Experts reveal pafolacianine...
06/01/2021
Oncology
ASNS Expression Predicts GLS1 Inhibitor Response in Ovarian Cancer
Podcasts
ASNS Expression Predicts GLS1 Inhibitor Response in Ovarian Cancer
04/23/2021
Nakia Spencer, MSc, discusses the ongoing trial of asparagine synthetase (ASNS) expression to predict patient response to the GLS1 inhibitor IPN60090 in ovarian cancer.
Nakia Spencer, MSc, discusses the ongoing trial of asparagine synthetase (ASNS) expression to predict patient response to the GLS1 inhibitor IPN60090 in ovarian cancer.
Nakia Spencer, MSc, discusses...
04/23/2021
Oncology
Safety and Efficacy of Vaccination With Folate Receptor Alpha for Ovarian Cancer
Videos
Safety and Efficacy of Vaccination With Folate Receptor Alpha for Ovarian Cancer
04/01/2021
Roisin O'Cearbhaill, MD, discusses the safety and efficacy of TPIV200 vs GM-CSF alone in patients with high-grade, platinum-sensitive ovarian cancer.
Roisin O'Cearbhaill, MD, discusses the safety and efficacy of TPIV200 vs GM-CSF alone in patients with high-grade, platinum-sensitive ovarian cancer.
Roisin O'Cearbhaill, MD,...
04/01/2021
Oncology
Niraparib as a Standard After First-Line Chemo for Advanced Ovarian Cancer
Podcasts
Niraparib as a Standard After First-Line Chemo for Advanced Ovarian Cancer
09/19/2020
Antonio Gonzalez-Martin, MD, discusses the PRIMA study of niraparib in patients with ovarian cancer.
Antonio Gonzalez-Martin, MD, discusses the PRIMA study of niraparib in patients with ovarian cancer.
Antonio Gonzalez-Martin, MD,...
09/19/2020
Oncology

Advertisement

Advertisement

Advertisement

Advertisement

Upcoming Events

October 5 ⁠–⁠ October 6
SMASH
October 14 ⁠–⁠ October 16
Lymphoma, Leukemia, and Myeloma
October 16 ⁠–⁠ October 19
October 19 ⁠–⁠ October 20
October 26 ⁠–⁠ October 27
October 29 ⁠–⁠ November 2
November 1 ⁠–⁠ November 2
November 6 ⁠–⁠ November 8
NEI Congress
November 7 ⁠–⁠ November 10
WoundCon
November 8
See Full Calendar

Advertisement

Advertisement

Advertisement

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use